Wide Field OCTA in Ocular Diseases (WOOD-2025)

Wide Field OCTA in Ocular Diseases: a Prospective Observational Study of the Clinical Impact of Wide Field OCTA in Ocular Disease.

The main retinal diseases, whether or not associated with specific mutations genetic, cause progressive degeneration of vascular retinal structures and not vascular, resulting in decreased visual function. Often, such diseases affect the noblest part of the retina, called macula. Many retinal diseases can be complicated by choroidal neovascularization which causes frequent bleeding and fluid leakage that accumulates in the subretinal and intraretinal spaces. Although the investigators know many details of each disease affecting the retina, very often the correct diagnostic framework can be complicated, given the presence of morphological elements common to the different pathologies. Similarly, predicting the effect of treatment and the patient's outcome is a constant challenge for the ophthalmologists. Most of the current research has been focused on the assessment of vascular alterations localized in the macula. However, growing evidence highlight the importance of peripheral vascular changes on the outcome of retinal diseases. These changes can be detected only be wide field OCT devices.

On the other hand, ocular inflammation and hyperemia represent major assessments in anterior segment disorders, such as dry eye disease. The current grading systems of ocular inflammation, redness and hyperemia are characterized by several limitations, thus making these evaluations still mainly confined to the subjective assessment performed by the ophthalmologist. However, the new generation OCT devices may include also an anterior segment module which can reconstruct anterior segment vessels, non-invasively, using the same technology described for retinal diseases.

The main goal of the study is to evaluate the diagnostic contribution of a new generation wide field OCTA device in ocular diseases, which has recently received CE marking. In particular, the investigators will evaluate this new generation device both in retinal and anterior segments diseases, testing for common points and differences with the standard of care non-invasive diagnostic devices. Secondary outcomes include the assessment of the correlation between the patient's visual function (visual acuity) and morphological changes (standard of care imaging assessment) highlighted by the wide field OCT device, with particular attention to microstructural differences between major ocular diseases and the possible development of non-invasive biomarkers, useful for the diagnosis and follow-up of such pathologies.

Study Overview

• Status: Not yet recruiting
• Conditions: Uveitis; Diabetic Retinopathy; Diabetic Macular Edema; Retinal Vein Occlusion; Geographic Atrophy; Myopia; Ocular Surface Disease; Stargardt Disease; Retinitis Pigmentosa (RP); Vitreoretinal Disease; Best Disease; Pachychoroid Disease; Central Serous Choroidopathy; Age - Related Macular Degeneration (AMD); Inherited Retinal Disease; Macular Neovascularisation

Detailed Description

Hypothesis: wide field OCT may remarkably contribute on the improvement of diagnostic workup and precision medicine of ocular diseases.

Design: Post-market medical device, monocentric trial. Both cross-sectional and prospective.

The number of study groups and study duration: patients affected by ocular diseases (age-related macular degeneration, diabetic retinopathy, inherited retinal dystrophies, uveitis, myopia, pachychoroid spectrum, dry eye) and healthy controls. Duration 2-years.

the investigators will not expect remarkable biases since our evaluation will be based on the statistical analysis of quantitative imaging metrics coming from the investigational device and the comparator devices.

Both patients and controls will undergo complete ophthalmology assessment and non-invasive imaging diagnostic investigation.

In this study, the investigators will employ one standard-of-care device-Heidelberg Spectralis for retinal imaging and Keratograph 4M for anterior segment evaluation-alongside DreamOCT as the comparator device, replacing the second standard-of-care device typically used in our clinic. This is accepted and agrees with study design since, for diagnostic devices, the procedure to obtain CE approval includes safety check and comparability with other existing devices. Hence, the above described procedure represents the standard of care methodology when testing a novel device in clinical practice.

• Study Type: Observational
• Enrollment (Estimated): 200

Contacts and Locations

• Study Contact: Name: Alessandro Arrigo, MD, PhD; Phone Number: +390226432648; Email: arrigo.alessandro@hsr.it

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: Yes

• Sampling Method: Non-Probability Sample

Study Population

Patients affected by ocular diseases and healthy controls to be considered as reference.

Description

Inclusion Criteria:

• Age > 18 years
• Both genders
• Confirmed diagnosis of one of the above diseases
• Age-related macular degeneration
• Diabetic retinopathy
• Myopia
• Pachychoroid spectrum disease
• Inherited retinal dystrophy
• Uveitis
• Dry eye
• Visual acuity of at least 1/20
• Signed informed consent for the participation to the trial.

Exclusion Criteria:

• Media opacities
• Any other eye or systemic condition that may irreversibly impair the results of the study
• Surgery in the eye in the study, including cataract extraction, in the three months prior to recruitment

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort
Patients affected by ocular diseases; Patients affected by one of the following: AMD, diabetic retinopathy, pachychoroid spectrum, inherited retinal diseases, uveitis, ocular surface disorders

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Retinal vessel density	Quantitative analysis of macular and peripheral capillary perfusion	Cross-sectional investigation at baseline and after 1-year follow-up
Conjunctival vessel density	Conjuctival perfusion in ocular surface diseases	Cross-sectional investigation at baseline and after 1-year follow-up

Collaborators and Investigators

• Sponsor: IRCCS San Raffaele

Study record dates

Study Major Dates

• Study Start (Estimated): January 1, 2026
• Primary Completion (Estimated): January 1, 2028
• Study Completion (Estimated): May 1, 2028

Study Registration Dates

• First Submitted: December 7, 2025
• First Submitted That Met QC Criteria: December 19, 2025
• First Posted (Estimated): December 23, 2025

Study Record Updates

• Last Update Posted (Actual): December 30, 2025
• Last Update Submitted That Met QC Criteria: December 22, 2025
• Last Verified: December 1, 2025

More Information

Terms related to this study

• Keywords: retinal disease; macular disease; ocular surface disease; quantitative imaging; wide-field octa; multimodal retinal imaging
• Additional Relevant MeSH Terms: Endocrine System Diseases; Vascular Diseases; Cardiovascular Diseases; Genetic Diseases, Inborn; Diabetes Mellitus; Eye Diseases; Diabetic Angiopathies; Diabetes Complications; Refractive Errors; Embolism and Thrombosis; Eye Diseases, Hereditary; Uveal Diseases; Retinal Dystrophies; Retinal Degeneration; Venous Thrombosis; Thrombosis; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Stargardt Disease; Retinal Diseases; Diabetic Retinopathy; Myopia; Retinitis Pigmentosa; Macular Degeneration; Uveitis; Geographic Atrophy; Retinal Vein Occlusion; Central Serous Chorioretinopathy; Vitelliform Macular Dystrophy
• Other Study ID Numbers: WOOD-2025

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO
• IPD Plan Description: There is not a plan to make IPD available

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No